- Home
- PMM vs ATAI Comparison
PMM vs ATAI Comparison
Compare PMM & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- ATAI
- Stock Information
- Founded
- PMM 1989
- ATAI 2018
- Country
- PMM United States
- ATAI Germany
- Employees
- PMM N/A
- ATAI N/A
- Industry
- PMM Investment Managers
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- ATAI Health Care
- Exchange
- PMM Nasdaq
- ATAI Nasdaq
- Market Cap
- PMM 251.7M
- ATAI 444.7M
- IPO Year
- PMM N/A
- ATAI 2021
- Fundamental
- Price
- PMM $6.15
- ATAI $4.61
- Analyst Decision
- PMM
- ATAI Strong Buy
- Analyst Count
- PMM 0
- ATAI 3
- Target Price
- PMM N/A
- ATAI $13.33
- AVG Volume (30 Days)
- PMM 118.3K
- ATAI 4.7M
- Earning Date
- PMM 01-01-0001
- ATAI 11-12-2025
- Dividend Yield
- PMM 4.68%
- ATAI N/A
- EPS Growth
- PMM N/A
- ATAI N/A
- EPS
- PMM 0.23
- ATAI N/A
- Revenue
- PMM N/A
- ATAI $2,309,000.00
- Revenue This Year
- PMM N/A
- ATAI $712.99
- Revenue Next Year
- PMM N/A
- ATAI N/A
- P/E Ratio
- PMM $26.52
- ATAI N/A
- Revenue Growth
- PMM N/A
- ATAI 510.85
- 52 Week Low
- PMM $5.00
- ATAI $1.03
- 52 Week High
- PMM $6.42
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- PMM 74.72
- ATAI 57.88
- Support Level
- PMM $6.04
- ATAI $4.50
- Resistance Level
- PMM $5.87
- ATAI $4.75
- Average True Range (ATR)
- PMM 0.05
- ATAI 0.28
- MACD
- PMM 0.03
- ATAI -0.04
- Stochastic Oscillator
- PMM 84.09
- ATAI 50.33
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.